Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
Enveric Biosciences, Inc. (ENVB)
Company Research
Source: Business Wire
Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digit royalties on future sales CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company has executed a licensing agreement with MycoMedica Life Sciences, out-licensing the Company’s EVM201 program, including drug candidate EB-002.Pursuant to the terms of licensing agreement, MycoMedica will seek to develop EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, in treatment of neuropsychiatric disorders such as depression. MycoMedica will receive an exclusive, global license to the formulations, drugs, method of use, and medical devices developed by Enveric to utilize the compound. Myc
Show less
Read more
Impact Snapshot
Event Time:
ENVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENVB alerts
High impacting Enveric Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ENVB
News
- Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds [Yahoo! Finance]Yahoo! Finance
- Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series CompoundsBusiness Wire
- Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior [Yahoo! Finance]Yahoo! Finance
- Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like BehaviorBusiness Wire
- Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results [Yahoo! Finance]Yahoo! Finance
ENVB
Sec Filings
- 12/18/24 - Form DEF
- 12/12/24 - Form PRER14A
- 11/27/24 - Form PRE
- ENVB's page on the SEC website